

PO Box 9905 Washington DC 20016 Telephone 202-362-1809

Another Flat Budget For NIH And NCI Despite Strong Bipartisan Support

By Kirsten Boyd Goldberg

The good news: NIH finally has an appropriation for FY2008, despite concerns that Congress would delay acting on funding bills until the spring.

The bad news: NIH received an increase of only 0.46 percent, not enough to keep up with the 3.7 percent inflation in biomedical research.

It was a deflating end to calendar year 2007 that began with efforts by members of Congress and scientific societies to push for a 6.7 percent increase for NIH for the fiscal year that began Oct. 1. In the fall, House and Senate conferees agreed on a 3.1 percent increase. Despite strong bipartisan support,
(Continued to page 2)

In the Cancer Centers:

Roswell Park Wins High Priority Score, Full Budget Recommendation For Core Grant

By Kirsten Boyd Goldberg

ROSWELL PARK CANCER INSTITUTE received five-year renewal of its NCI Cancer Center Support Grant, with peer reviewers awarding the highest priority score the center has ever received and recommending full funding of its requested budget.

RPCI received a score of 159, in the "excellent" range. Cancer center grants, like most NIH grants, are awarded priority scores from 100 to 500, with 100 being a perfect score.

"The receipt of a superb score on the renewal of our NCI core grant is testament to the outstanding work of the Roswell Park team and affirms that we are committed to conducting innovative and pioneering research and providing exemplary patient care," said **Donald Trump**, RPCI president and CEO. "These are the attributes of a world-class cancer center and we are proud that the NCI has recognized the quality of our cancer programs and faculty."

RPCI, founded in 1898, was one of three centers that served as a model for the NCI Cancer Centers Program, which manages the CCSGs, also known as core grants. RPCI has been funded as an NCI-designated comprehensive cancer center without interruption since 1974.

However, eight years ago, RPCI faced a potential crisis with its NCI core grant. The center had begun a difficult process of changing its relationship with the state of New York, which funded the center as an arm of the state health department. Site visitors weren't so sure the center and its director at
(Continued to page 2)

NCI Budget: Institute Receives 0.15 Percent Increase For FY2008

... Page 2

In the Cancer Centers: Edelson To Step Down As Yale Center Director; Ozols To Advise Fox Chase President

... Page 3

FDA News: New Safety Concerns On ESAs Prompt FDA To Consult ODAC Again

... Page 5

Societies & Foundations: Love Foundation Receives \$1 Million Anonymous Gift

... Page 5

Funding Opportunities: Armstrong Foundation Seeks Grant Applicants

... Page 6

NCI FY08 Appropriation Flat At \$4.8B, Budget Cuts Planned

(Continued from page 1)

the funding didn't survive President Bush's Nov. 13 veto of the Labor-HHS-Education appropriations bill.

Left no choice but to cut funds from the appropriations bills to reach levels acceptable to the White House, Congress rolled 11 of 12 funding bills into one huge Consolidated Appropriations Act for FY2008 last month. Bush signed the act into law on Dec. 26.

Under the act, NIH receives an overall appropriations \$29.229 billion, but has to transfer \$196 million to the Global AIDS fund in FY08.

That leaves NIH with a programmatic budget of \$28.942 billion, an increase of \$133 million, or 0.46 percent, over FY2007.

Language requiring public access to research data remained in the appropriations act. The act requires investigators funded by NIH "to submit or have submitted for them to the National Library of Medicine's PubMed Central an electronic version of their final, peer-reviewed manuscripts upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication" (The Cancer Letter, Nov. 2, 2007).

NCI receives an FY08 appropriation of \$4.8 billion, an increase of \$7.4 million—only 0.15 percent—over last year.

With essentially no increase, NCI has little budgetary flexibility, since over 80 percent of its budget

already committed to ongoing grants and other projects. Also, NIH and HHS can remove millions from the budget through taps. NCI officials have estimated that up to \$20 million could be taken out of its budget by NIH alone this year.

NCI has lost 12 percent of its purchasing power since FY2004 and for the past few years has taken cuts in current programs to fund new scientific projects, NCI Director John Niederhuber told the institute's advisory groups last fall (The Cancer Letter, Nov. 23, 2007).

Niederhuber said he planned to impose a 3 percent across-the-board cut to NCI programs in FY08 to create a reserve of about \$70 million for new projects. However, that scenario was based on Congress providing NCI with a 2.67 percent increase.

NIH officials were to meet this week to decide on grant funding policies for the fiscal year.

The text of the bill is available at http://www.rules.house.gov/110_fy08_omni.htm.

NIH institute and center funding levels can be found at <http://opa.faseb.org/pages/WashingtonUpdate/Dec2107/page2.htm>.

In the Cancer Centers: Since Reorganization, RPCI Has Recruited 160 Scientists

(Continued from page 1)

the time, **David Hohn**, could pull through and recruit the scientists needed for a fully functional comprehensive cancer center. RPCI's core grant was renewed but funded provisionally for three years, instead of five years.

In 2003, the core grant was renewed for five years. In the latest review, RPCI's scores improved in more than 25 areas compared to the 2003 review.

Trump said the current success in peer review was a "culmination of the hard work" by Hohn and others over the past eight years. "It was the prior relationship with the state that proved a substantial barrier to the ability to recruit scientists," Trump said. "Now, the impact of the reorganization has been felt in the recruitment of 160 scientists in eight to 10 years—a lot of young folks with vibrant scientific programs."

RPCI continues to receive support from the state, but reports to an independent board. "We are now functioning as a completely independent, freestanding cancer center with a good relationship with the state," Trump said.

"This highly competitive award underscores Roswell Park's national and international reputation as



© The Cancer Letter is a registered trademark.

Editor & Publisher: Kirsten Boyd Goldberg

Editor: Paul Goldberg

Editorial Assistant: Shelley Whitmore Wolfe

Editorial: 202-362-1809 **Fax:** 202-318-4030

PO Box 9905, Washington DC 20016

Letters to the Editor may be sent to the above address.

Subscriptions/Customer Service: 800-513-7042

PO Box 40724, Nashville TN 37204-0724

General Information/FAQ: www.cancerletter.com

Subscription \$375 per year worldwide. ISSN 0096-3917. Published 46 times a year by The Cancer Letter Inc. Other than "fair use" as specified by U.S. copyright law, none of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form (electronic, photocopying, or facsimile) without prior written permission of the publisher. Violators risk criminal penalties and damages.

Founded Dec. 21, 1973, by Jerry D. Boyd.

a premier comprehensive cancer center with excellence in basic, clinical and population sciences and is tribute to the resurgence of Roswell Park,” said Michael Joseph, chairman of the RPCIC Board of Directors.

To be designated a comprehensive cancer center by NCI, a cancer center must demonstrate depth and breadth of research activities in each of the three major areas of cancer research including basic, clinical, and prevention, control, and population-based research. Centers also must maintain a strong body of interactive research that bridges these scientific areas.

In clinical research, a comprehensive cancer center must conduct early-phase, innovative clinical trials and provide leadership and accrue patients to these trials. A center also must provide outreach, education, and information on cancer to the community it serves.

RPCI’s renewal involved submitting a 1,100-page grant application and an on-site visit last September from NCI peer reviewers.

The NCI grant will support six programs and 13 core resources at RPCI, Trump said. “We won’t know for a while how much we will get, but the fact that no budget cuts were recommended is a very good sign of the recognition by peer reviewers that we pulled together a full program,” he said. “This was a real milestone for us.”

RICHARD EDELSON, director of the Yale Cancer Center, plans to step down and return to his position as chairman of the Department of Dermatology, Yale Medical School Dean **Robert Alpern** announced in an email to colleagues. Edelson has directed the center since 2003.

“Yale Cancer Center, under Rick’s guidance and leadership, has completely reorganized itself during the past three years, and it has recently achieved a five-year renewal of its core grant from the NCI,” Alpern wrote. “Rick and his senior colleagues have recruited close to a dozen top-echelon clinician faculty members in Medical Oncology and have helped build complementary strength with their colleagues in Surgery, Therapeutic Radiology and other Yale departments with a significant stake in cancer.

“We owe Rick an extraordinary debt of gratitude,” Alpern wrote. “At the time of the last search for a director, in 2002-2003, there were significant issues facing the center which caused real concern within the institution as to whether the core grant would be renewed. Rick selflessly agreed to take over, fixed the problems and renewed the grant. Meanwhile, construction of the 14-story Smilow Cancer Hospital has

gotten under way and is on schedule to open in 2009, filling a major gap in the center’s clinical capability. The center is in a much stronger position now, and the next director will have major opportunities to advance cancer research and cancer care both at Yale and on the national and international stage.”

Edelson, a principal investigator in cancer immunology, will continue to direct the center during the search for a successor, Alpern wrote.

ROBERT OZOLS will be stepping down as senior vice president and chief clinical officer of Fox Chase Cancer Center. Ozols will remain as chief clinical officer until a successor is named and will assume the role as senior advisor to the president.

Fox Chase began a national search for a new chief clinical officer shortly after Ozols announced his upcoming retirement last fall. The identification of a new clinical leader will be accompanied by a significant expansion of clinical space within the center.

Ozols joined Fox Chase in 1988 as chairman of medical oncology. He became senior vice president for medical science and medical director of the Hospital of Fox Chase Cancer Center in 1993. In 2002, he became the first to fill the Audrey Weg Schaus and Geoffrey Alan Weg Chair in Medical Science at Fox Chase.

For nine years, Ozols served as principal investigator for Fox Chase Cancer Center’s Specialized Program of Research Excellence grant in ovarian cancer from NCI.

Ozols’ research has focused on how cancer cells develop drug resistance and on strategies for overcoming it. He has developed new clinical approaches to treating women with ovarian cancer, including new chemotherapy regimens that combine paclitaxel and carboplatin as well as pharmacologic techniques to reverse resistance of tumors to anticancer drugs.

Before coming to Fox Chase in 1988, Ozols had headed the experimental therapeutics section of the NCI Medicine Branch since 1984. He joined the branch in 1976 as a clinical associate. Ozols held the rank of medical director (captain) in the Public Health Service, receiving the PHS Outstanding Unit Award in 1984 and 1988 and a PHS Commendation Medal in 1987.

Born in Latvia in 1944, Ozols earned his B.S. in chemistry in 1966, his Ph.D. in biochemistry in 1971, and his M.D. in 1974 at University of Rochester. He completed his internship and residency at Dartmouth-Hitchcock Medical Center.

ROBERT UZZO, urologic oncologist and vice

chairman of the Department of Surgical Oncology at Fox Chase Cancer Center, was named acting chairman of the department. In 2003, Uzzo was promoted from associate member to member with tenure in the Fox Chase Division of Medical Science. He replaces **Monica Morrow**, who will join Memorial Sloan-Kettering Cancer Center as co-director of the Breast Cancer Program and chief of the Breast Surgery Service.

OHIO STATE UNIVERSITY **President E. Gordon Gee** announced two changes in leadership to the university's cancer program. In the restructuring, the leadership of the research and clinical components of the cancer program will be consolidated into one position, with **Michael Caligiuri** succeeding **David Schuller** as chief executive officer of The James.

Schuller has been appointed vice president for medical center expansion and outreach by **Wiley "Chip" Souba Jr.**, interim senior vice president and executive dean for health sciences and CEO of the medical center. Schuller will retain his position as medical director of the medical center's development campaign.

"It is clear that the priorities and objectives of the cancer program are critical to achieving the goals of the medical center and university," said Gee. "This new alignment puts two of our most talented cancer leaders in roles that give us the greatest potential and opportunities for accomplishing our mutual goals."

Caligiuri, who will report to Gee, will be responsible for all administrative, financial, and operational aspects of The James. He also will continue as director of the Ohio State Comprehensive Cancer Center and in that capacity report to **Joseph Alutto**, university executive vice president and provost.

Schuller will continue to work on the executive planning team for the medical center's master facilities plan as it develops the new footprint for the larger center scheduled for construction during the next five to seven years. Schuller will hold the title of CEO emeritus of the James and director emeritus of the cancer center, which he directed from 1977 to 1998.

In its most recent review by NCI, the cancer center received the highest possible score and a \$19.2 million grant renewal, the university said.

GEORGE CANELLOS, the William Rosenberg Professor of Medicine at Harvard Medical School and founding chief of medical oncology at Dana-Farber Cancer Institute, was awarded the 2007 Karl Musshoff Prize for lifetime achievements in the field of Hodgkin's lymphoma. He received the honor Nov. 4 at the 7th

International Conference on Hodgkin's Lymphoma in Cologne. He was previously honored with the San Salvatore Award, given every three years at the International Conference on Malignant Lymphoma.

CHANDRA BELANI was named deputy director, Penn State Cancer Institute at Penn State Milton S. Hershey Medical Center, and Miriam Beckner Distinguished Professor of Medicine, Penn State College of Medicine. Belani was head of the Lung Cancer Program and Early Phase Clinical Investigations at the University of Pittsburgh Cancer Institute. Penn State Cancer Institute is a partnership founded by Penn State Hershey Medical Center, The Pennsylvania State University, Lehigh Valley Hospital and Health Network, and Mount Nittany Medical Center.

DENNIS RUSCH was named chief financial officer for City of Hope. Rusch was area and group chief financial officer at South Texas Health System. Prior to that, he was chief financial officer and vice president of finance at Roswell Park Cancer Institute.

GERD PFEIFER, co-leader of the Cancer Biology Program and professor and chairman, Division of Biology at City of Hope, was named first holder of the Lester M. and Irene C. Finkelstein Chair in Biology.

The \$2 million endowment from the longtime supporters will fund basic research in cancer. Pfeifer, known for identifying the molecular link between cigarette smoking and lung cancer, recently received the largest of eight national grants from NIH as part of The Cancer Genome Atlas. The project develops technologies to detect and treat cancer.

In the pilot phase of the project, Pfeifer and investigators at Johns Hopkins University, Stanford, and other institutions will focus on genetic changes associated with lung, ovarian and brain cancers.

MULTIPLE MYELOMA Research Consortium said it awarded the 2007 MMRC Center of the Year Award to Emory University and **Sagar Lonial**, associate professor at Winship Cancer Institute. The award recognizes a MMRC Member Institution and its principal investigator for advancing the field of multiple myeloma research and drug development.

—*Shelley Whitmore Wolfe contributed to this report.*

News items for In the Cancer Centers and other news columns in The Cancer Letter may be emailed to news@cancerletter.com.

FDA News:
New Safety Concerns On ESAs Prompt FDA To Consult ODAC

By Paul Goldberg

Two studies pointing to increased mortality and disease progression from erythropoiesis-stimulating agents will cause FDA to seek guidance from an advisory committee, the agency announced.

Initially, the agency communicated its plans to the sponsors, who are obligated to share such development with the public (The Cancer Letter, Dec. 7, 2007). Then, on Jan. 3, FDA issued a press release stating that the most recent studies amplify the safety concerns observed in six studies now listed on the ESA label.

“Taken together, all eight studies show more rapid tumor growth or shortened survival when patients with breast, non-small cell lung, head and neck, lymphoid or cervical cancers received ESAs compared to patients who did not receive this treatment. In all of these recent studies, ESAs were administered in an attempt to achieve a hemoglobin level of 12 g/dL or greater, although many patients did not reach that level,” the agency said in a statement.

FDA said it plans to present the data to an advisory committee “in the next few months,” but didn’t disclose the date. According to the agency’s meeting calendar, the next meeting of the Oncologic Drugs Advisory Committee is tentatively scheduled for March 13.

“This new information further underscores the safety concerns regarding the use of ESAs in patients with cancer, which FDA addressed in previous communications,” Janet Woodcock, FDA’s deputy commissioner for scientific and medical programs, chief medical officer, and acting director of the Center for Drug Evaluation and Research, said in a statement.

“FDA is reviewing these data and may take additional action. In the meantime, FDA recommends that health care providers review the risks and benefits of ESAs outlined in the product label and discuss this information with their patients,” Woodcock said.

The agency’s decisions to communicate the latest safety concerns directly to the public and to return ESAs to the advisory committee for the second time in 10 months is consistent with the agency’s pattern of swift, public response to safety signals related to these widely used drugs.

Last year, FDA revised the ESA label twice, cautioning against using the drug to treat anemia of cancer, eliminating all references to symptom improvement in oncology and nephrology, and urging

doctors to set lower hemoglobin targets use smaller amounts of the drug.

Last May, ODAC agreed with the agency’s contention that the impact of ESAs differs from setting to setting, opening the door for restricting the use of these agents in some diseases (The Cancer Letter, May 11, May 18, 2007).

The agency’s swift response to bad news lends support for the Centers for Medicare and Medicaid Services, which instituted a National Coverage Decision that lowers the hemoglobin targets for administration of ESAs. The sponsors of the drugs as well as cancer groups that include the American Society of Clinical Oncology have been urging CMS to reverse that decision.

The latest safety concerns emerge from studies of breast and cervical cancer:

—On Nov. 30, Amgen Inc., the manufacturer of Aranesp, Epogen, and Procrit, provided FDA with information from the 733-patient PREPARE study of women who received neoadjuvant chemotherapy. After three years, 14 percent of the patients who received Aranesp had died, compared to 9.8 percent who did not receive the drug. Tumor growth was also faster in patients receiving Aranesp. A formal statistical analysis of the study is expected in 2009.

—On Dec. 4, Amgen informed FDA of the results of a study by the NCI Gynecologic Oncology Group of chemotherapy and radiation for advanced cervical cancer. The patients were administered either Procrit, a drug licensed to Johnson & Johnson, to maintain hemoglobin levels above 12 g/dL, or blood transfusions as needed. After three years, 66 percent of the patients who did not take Procrit were alive and free of cancer growth, compared to 58 percent who had received the drug. The study closed prematurely with less than 25 percent of planned enrollment, because of concerns about thromboembolic events.

Both studies sought to increase hemoglobin above 12 g/dL, the upper limit noted on the ESA label.

Societies & Foundations:
Love Foundation Receives \$1 Million Anonymous Gift

DR. SUSAN LOVER RESEARCH FOUNDATION received a \$1 million gift from an anonymous donor in honor of **Erin Daniels** and **Leisha Hailey**, two stars of the Showtime series, “The L Word,” for the realism and truth they brought to a breast cancer storyline that ended with the death of Daniels’ character, Dana Fairbanks.

This is the largest private donation ever made to

the foundation, said **Naz Sykes**, executive director. The donation will be used to establish The Erin Daniels and Leisha Hailey Fund for Breast Cancer. The donor intends to match dollar-for-dollar every donation made to the fund, which will be used to advance the foundation's research program.

Foundation President Love guest-starred on "The L Word" after Dana was diagnosed with breast cancer. "After I was on the show, the donor visited our website and began to educate herself about the intraductal research we are doing," said Love. "We are honored that she has decided to make this donation and to establish this fund. It will make research we could only dream of doing over the next few years a reality."

The foundation also recently received a \$1.2 million research grant from The Avon Foundation for a project to develop a breast fluid test to identify premenopausal women at risk for breast cancer.

KAREN KAPLAN was named executive director of Ovarian Cancer National Alliance. She was director of special projects for the Wye River Group on Healthcare, a national health care reform organization, where she created and implemented policy projects. Prior to that, she served as a consultant to the American Cancer Society on palliative care policies and was director of its Access to Care Project. Kaplan, whose appointment for OCNA begins Feb. 4, is replacing **Sherry Black**.

JON RETZLAFF, legislative director for the Federation of American Societies for Experimental Biology since 2004, will join Lewis-Burke Associates, LLC, a government relations firm in Washington, D.C., on Feb. 1.

Retzlaff will lead the health and biomedical research practice of the firm, joining **Donna Dean**, formerly the founding director of the National Institute of Biomedical Imaging and Bioengineering, to advise university and research-oriented clients.

Prior to joining FASEB, Retzlaff was executive officer of the National Library of Medicine. Earlier in his NIH career, he was a senior legislative advisor to the National Institute of Neurological Disorders and Stroke. He also worked for both House and Senate Appropriations Subcommittees on Labor, Health and Human Services, Education and Related Agencies and served in the HHS Office of the Assistant Secretary for Legislation.

AMERICAN SOCIETY OF HEMATOLOGY presented awards Dec. 9 at its annual meeting in Atlanta.

Ernest Beutler, chairman, Department of Molecular and Experimental Medicine, The Scripps Research Institute, is the first recipient of the Wallace H. Coulter Award for Lifetime Achievement in Hematology. The award recognizes a lifetime commitment and contribution to hematology. Beutler originated the concept of X-chromosome inactivation in human females. **William Vainchenker**, of Institut Gustave Roussy, Villejuif, France, received the William Dameshek Prize for his research on the genetics of myeloproliferative diseases. **Carlo Croce**, of Ohio State University School of Medicine, received the Henry M. Stratton Medal for a distinguished career in hematology and for the discovery of the workings of the MYC oncogene in Burkitt's lymphoma. **Edward Benz Jr.**, president and CEO of Dana-Farber Cancer Institute, received an ASH Mentor Award in Basic Science for the training and the career development of hematologists early in their careers.

BRUCE ALBERTS, president emeritus of the National Academy of Sciences and chairman of the National Research Council (1993-2005), was named editor-in-chief of the journal *Science* by the Board of Directors of the American Association for the Advancement of Science, effective March 1.

Alberts, professor of biochemistry and biophysics at the University of California, San Francisco, succeeds **Donald Kennedy**, president emeritus of Stanford University and a former FDA commissioner.

AMERICAN ASSOCIATION FOR CANCER RESEARCH has begun *Cancer Prevention Research*, a peer-reviewed scientific journal dedicated to cancer prevention, from preclinical research to clinical trials. The editor-in-chief is **Scott Lippman**, of M. D. Anderson Cancer Center.

Funding Opportunities:

Lance Armstrong Foundation requests proposals for its 2008 grants cycle. Applicants must submit a letter of intent.

Community Grants. Letter of Intent submission date: Jan. 28 through March 24. One-, two- or three-year grants for up to \$150,000. Applications will be considered in two areas of cancer survivorship: Evidence-based interventions or education for healthcare professionals.

General research grants and Young Investigator grants. Letter of Intent submission date: Feb. 4 through March 14. The general research grants will consist of up to \$75,000/year for up to three years to support research projects initiated by established investigators. Young Investigator grants would support career development in the field of cancer survivorship research. The LAF will grant Young Investigator research

grants of up to \$50,000/year for up to two years. Inquiries for all grants: www.livestrong.org/GrantCycle.

NCI RFAs

RFA-CA-08-504: Limited Competition: Adult Brain Tumor Clinical Trials Consortium. U01. Letters of Intent Receipt Date: Jan. 29. Application Receipt Date: Feb. 29. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-504.html>. Inquiries: Jeffrey Abrams, 301-496-2522; abramsj@mail.nih.gov.

RFA-CA-08-006: Innovative Technologies for Molecular Analysis of Cancer. R21. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-006.html>. Letters of Intent Receipt Date: Feb. 11; April 29; Aug. 24. Application Receipt Dates: March 11; May 29; Sept. 24. Inquiries: Richard Aragon, 301-496-1550; Araragon@mail.nih.gov.

RFA-CA-08-007: Application of Emerging Technologies for Cancer Research. R21. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-007.html>. Inquiries: Richard Aragon, 301-496-1550; Araragon@mail.nih.gov.

RFA-CA-08-008: Application of Emerging Technologies for Cancer Research. R33. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-008.html>.

RFA-CA-08-009: Innovative Technology Solutions to Cancer Sample Preparation. R21. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-009.html>. Inquiries: Richard Aragon, 301-496-1550; Araragon@mail.nih.gov.

RFA-CA-08-010: Innovative Technology Solutions to Cancer Sample Preparation. R33. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-010.html>.

RFA-CA-08-011: Innovative and Applied Molecular Analysis Technologies for Cancer. STTR R41/42. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-011.html>. Inquiries: Richard Aragon, 301-496-1550; Araragon@mail.nih.gov.

RFA-CA-08-012: Innovative and Applied Molecular Analysis Technologies for Cancer. SBIR R43/44. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-011.html>.

RFA-CA-08-013: Innovative Technology Solutions to Cancer Sample Preparation. SBIR R43/44. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-013.html>.

RFA-CA-08-014: Innovative Technology Solutions to Cancer Sample Preparation. STTR R41/42. Full text: <http://www.grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-014.html>.

Program Announcements

PAR-08-046: NIDA Research Center of Excellence Grant Program. P50. Letters of Intent Receipt Date: Jan. 28. Application Receipt or Submission Date: Feb. 26. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAR-08-046.html>. Inquiries: Glen Morgan, 301-496-8585.

PA-08-044: Human Pluripotent Stem Cell Research Using Non-Embryonic Sources. R21. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PA-08-044.html>. Inquiries: David Owens, 301-496-1447; do47h@nih.gov.

PAR-08-045: Outcomes, Cost-Effectiveness and the Decision Making Process to Use Complementary and Alternative Medicine. R01. Application Submission/Receipt Date: May 19, May 19, 2009, May 19, 2010. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAR-08-045.html>. Inquiries: Wendy Nelson, 301-435-4590; nelsonw@mail.nih.gov.

PA-08-052: Nanoscience and Nanotechnology in Biology and Medicine. R01. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PA-08-052.html>. Inquiries: Piotr Grodzinski, grodzinp@mail.nih.gov.

PA-08-053: Nanoscience and Nanotechnology in Biology and Medicine. R21. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PA-08-053.html>.

PAR-08-047: NCI Transition Career Development Award to Promote Diversity. K22. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAR-08-047.html>. Inquiries: Belinda Locke, 301-496-7344; lockeb@mail.nih.gov.

PAS-08-048: Understanding and Preventing Brain Tumor Dispersal. R01. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAS-08-048.html>. Inquiries: William Timmer, 301-496-8866; timmerw@mail.nih.gov.

PAS-08-049: Understanding and Preventing Brain Tumor Dispersal. R21. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAS-08-049.html>.

PAR-08-065: NIH Revision Awards for Studying Interactions Among Social, Behavioral, and Genetic Factors in Health. R01. Letters of Intent Receipt Date: April 13. Application Submission/Receipt Date: May 13. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAR-08-065.html>. Inquiries: Tanya Agurs-Collins, 301-594.6637; collinsta@mail.nih.gov.

PAR-08-066: NIH Revision Awards for Studying Interactions Among Social, Behavioral, and Genetic Factors in Health. R21. Full text: <http://www.grants.nih.gov/grants/guide/pa-files/PAR-08-066.html>.

RFPs

RFP N01-RC-81009-16: Identification, Referral and Follow-up of Patients who have HLTV-1 Associated Adult T-Cell Leukemia/Lymphoma. Full text: <http://www.fbdaily.com/archive/2007/12-December/16-Dec-2007/FBO-01470124.htm>. Annmarie Keane, 301-435-3814, ak155a@nih.gov, or Richard Hartmann, 3301-496-8620, rh75f@nih.gov.

RFP S08-054A: Cancer Genome Characterization. Response Due date: Jan 31. Full text: <http://www.fbdaily.com/archive/2007/12-December/22-Dec-2007/FBO-01473837.htm>. Inquiries: Jeanne Lewis, 301-228-4007, lewisjk@mail.nih.gov, or Shannon Jackson, 301-228-4022, sjackson@mail.ncifcrf.gov.



NCCN brings the learning to you at www.nccn.org/interactive

Access These Activities Today!

Access free, continuing education activities with our online, interactive learning center.

Highlights include presentations from the following:


- ◆ NCCN 12th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™
- ◆ NCCN 2nd Annual Congress: Hematologic Malignancies™
- ◆ NCCN Regional Guidelines Symposia
- ◆ NCCN Task Force Reports

NCCN interactive learning includes presentation webcasts, streaming videos, podcasts, and an audio library.

NCCN presentations are approved for AMA PRA Category I Credit™ and are also approved for nursing contact hours.



Paul F. Engstrom, MD, FACP
Fox Chase Cancer Center



Mohammad Jahanzeb, MD
St. Jude Children's Research Hospital/
University of Tennessee Cancer Institute



Beryl McCormick, MD
Memorial Sloan-Kettering
Cancer Center



John H. Ward, MD
Huntsman Cancer Institute
at the University of Utah

WEB-N-0242-1107

Visit www.nccn.org/interactive for more information or to access these programs.

Distribution Policy for The Cancer Letter

Thank you for your purchase of this issue of The Cancer Letter! Because issue and subscription sales are our major source of revenue, we wouldn't be able to provide you with the information contained in this newsletter without your support. If you have any questions or comments about the articles, please contact the editors (see page 2 of your issue for contact information).

We welcome your use of the newsletter and encourage you to send articles once in a while to colleagues. But please don't engage in routine distribution of The Cancer Letter to the same people week after week, unless your organization has purchased a site license or group subscription. If you aren't sure, ask the person who is paying for this subscription. If you are sending the newsletter to an unauthorized list, please stop; your actions are against Federal law. If you received this newsletter under an unauthorized arrangement, know that you are in receipt of stolen goods. Please do the right thing and purchase your own subscription.

If you would like to report illegal distribution within your company or institution, please collect specific evidence from emails or photocopies and contact us. Your identity will be protected. Our goal would be to seek a fair arrangement with your organization to prevent future illegal distribution.

Please review the following guidelines on distribution of the material in The Cancer Letter to remain in compliance with the U.S. Copyright Act:

What you can do:

- Route a print subscription of the newsletter (original only) or one printout of the PDF version around the office.
- Copy, on an occasional basis, a single article and send it to a colleague.
- Consider purchasing multiple subscriptions. We offer group rates on email subscriptions for two to 20 people.
- For institution-wide distribution or for groups larger than 20, consider purchasing a site license. Contact your librarian or information specialist who can work with us to establish a site license agreement.

What you can't do without prior permission from us:

- Routinely copy and distribute the entire newsletter or even a few pages.
- Republish or repackage the contents of the newsletter in any form.

If you have any questions regarding distribution, please contact us. We welcome the opportunity to speak with you regarding your information needs.

The Cancer Letter
PO Box 9905
Washington DC 20016
Tel: 202-362-1809
www.cancerletter.com